Background Clinical management of Ebola virus disease remains challenging. Routine laboratory analytics are often unavailable in the outbreak setting, and few data exist for the associated haematological and biochemical abnormalities. We aimed to assess laboratory and clinical data from patients with Ebola virus disease to better inform cli nical management algorithms, improve understanding of key variables associated with outcome, and provide insight into the pathophysiology of Ebola virus disease.
Introduction
Ebola virus disease is caused by an RNA fi lovirus, and is characterised by a febrile illness (recorded in 87% of patients with Ebola virus disease), often progressing to diarrhoea (67%), vomiting (66%), and, sometimes, haemor rhage (18%). 1 The current outbreak in west Africa is the largest up to now, with more than 27 500 cases (Aug 2, 2015). 2 Clinical and public health management is challenging, especially in the worst hit countries of Sierra Leone, Liberia, and Guinea, because of severity of clinical presentation, infection control concerns, poor healthsystem infrastructure, and high population density. 3, 4 There is currently no proven treatment for Ebola virus disease; therefore, management is supportive, inc luding administration of oral and intravenous fl uids and electrolytes, management of co-infections, and symptom control. [3] [4] [5] Ebola virus disease causes marked biochemical abnormalities, which might be amenable to simple interventions, potentially reducing the high case fatality rate. 4, [6] [7] [8] [9] [10] [11] [12] Because of the low-resource setting of outbreaks and risks associated with the collection and processing of laboratory samples, few data exist for these abnormalities, mostly from animal models, small cohorts, or case studies from resource-rich settings. [6] [7] [8] [9] 11, 13 Kerry Town Ebola treatment centre, operated by Save the Children, opened on Nov 5, 2014, in Sierra Leone off ering supportive care focused on fl uid and electrolyte management, in accordance with WHO guidelines. 3 This included haematology and biochemistry testing for all admissions from Dec 8, 2014 . We aimed to report data for clinical presentation, laboratory abnormalities, and their association with mortality in patients admitted in 1 month. We hoped these data would improve understanding of key variables associated with outcome, inform clinical management algorithms, and provide insight into the pathophysiology of Ebola virus disease.
Methods

Study design
We undertook a cohort study of patients consecutively admitted to Kerry Town Ebola treatment centre between Dec 8, 2014 , and Jan 9, 2015. During this period only patients with Ebola virus disease confi rmed at other isolation or community care centres were admitted. We used a standard case defi nition as per WHO guidelines. 2 All patients were included in the study except for those who were dead on arrival, or those who had no blood results within 24 h of admission. Primary outcome measure was discharge from the Ebola treatment centre.
Blood analysis
Samples were analysed at the on-site laboratory run by Public Health England and the UK Defence Medical Services. The Piccolo Express system (Abaxis, CA, USA) was used to generate metabolic and liver function profi les. An assay with biochemistry and liver function profi le was mainly used (Amylyte 13), though some samples were processed on a separate assay that included lactate, magnesium, calcium, and phosphate but excluded liver function profi le (Metlac 12). Laboratory scientists selected the assay based on availability, unless clinically requested. Haematology samples were processed with a Horiba ABX Micros ES60 analyser (Horiba, Montpellier, France). Reversetranscriptase-PCR (RT-PCR) assays for diagnosis of Ebola virus disease were done with the Altona RealStar Filovirus RT-PCR Kit (Altona, Hamburg, Germany), after inactivation and manual RNA extraction. Positive results were reported as cycle threshold values. All patients had a repeat RT-PCR on admission.
Data collection
All data were collected as part of routine patient care, and recorded on standardised forms, which were kept securely. Data extracted for research purposes were anonymised and stored on a password-protected database. The Sierra Leone ethics and scientifi c review committee provided study approval.
Clinical staging and management
All patients were assigned a disease stage on admission according to their clinical features. The staging system (table 1) was developed by the UK Defence Medical Services in reference to WHO guidelines and the proposed pathogenesis of Ebola virus disease. 3, [12] [13] [14] [15] Children were staged with a similar system, informally adapted to include paediatric indicators of dehydration as per WHO. 3 Standardised therapy was given to all patients based on disease stage. Targeted electrolyte replacement was provided based on biochemistry results. Patients were discharged once asymptomatic for
Research in context
Evidence before this study We did a systematic search of Medline and PubMed for previous studies published between May 1, 1976 , and May 1, 2015, reporting haematological and biochemical abnormalities in human beings with the following keywords: "Ebola", "Zaire ebolavirus", "viral haemorrhagic fever", "laboratory abnormalities", "haematology", "biochemistry", and "outcomes". We found two peer-reviewed studies that reported biochemistry data for small samples of non-consecutive cases of Ebola virus disease.
Before our study, Ebola virus disease was known to be associated with substantial organ dysfunction aff ecting the renal and hepatic systems, evidenced by the fi nding of increased creatinine, alanine transaminase, and aspartame transaminase in patients with Ebola virus disease when compared with negative controls. Increased aspartate transaminase and creatinine were associated with mortality in bivariate analysis. Aspartate transaminase to alanine transaminase ratio was high in patients with Ebola virus disease, possibly suggesting diff use cellular damage.
Added value of this study
This is the largest and most complete dataset of laboratory parameters in Ebola virus disease published up to now, and the fi rst to report haematological parameters and independent risk factors for mortality. The robust dataset allows for assessment of prevalence of organ dysfunction and electrolyte abnormalities for the fi rst time. Our key fi ndings were that high viral load and severe acute kidney injury are independent risk factors for mortality; Ebola virus disease is associated with a high prevalence of organ dysfunction, especially acute kidney injury, which is present even in early disease and in the absence of gastrointestinal symptoms. Additionally, we report a high prevalence of marked electrolyte imbalance in all stages of Ebola virus disease and common haematological abnormalities include mild thrombocytopenia, lymphocytosis, and raised haematocrit levels.
Implications of all available evidence
The clinical course of Ebola virus disease is variable, complex, and involves multisystem dysfunction. The high prevalence of electrolyte abnormalities and acute kidney injury reinforce the role of individual biochemistry measurement, targeted electrolyte support, and aggressive maintenance of volume status, which is achievable within the Ebola treatment clinic context following recent advances in portable laboratory analytics. Expert consensus would suggest this enhanced care is likely to improve case fatality rates as in other acute critical illnesses and this should become standard practice for Ebola virus disease case management.
In combination with therapeutic studies further characterisation of the aetiology of acute kidney injury is a priority, given it's association with mortality and potential reversibility. Future research studies should also investigate Ebola virus disease associated coagulopathy given the high prevalence of bleeding. 72 h with negative repeat blood Ebola RT-PCR. Acute kidney injury was defi ned according to RIFLE criteria. 16 To estimate baseline creatinine, we used the Modifi cation of Diet in Renal Disease (MDRD) for adults, 17 and the Schwartz calculation for children. 18 For alanine transaminase and aspartate transaminase, high was defi ned as between fi ve and 15 times the upper limit of normal, and very high or severe was defi ned as more than 15 times the upper limit of normal. Ebola virus RT-PCR cycle threshold value was categorised as low (<20 cycles) or high (≥20 cycles) with low cycle threshold indicating high viral load.
Statistical analysis
We reported descriptive analyses as frequencies, proportions, means, or medians. We used χ², t test, and Wilcoxon rank-sum for comparisons. We assessed risk factors for mortality with logistic regression. A-priori variables and those associated with mortality in univariate analysis (p<0·1) were assessed in a multivariate model. Interactions were assessed with likelihood ratio tests and no interaction terms contributed to the model. Adjustment was not made for missing data because biochemical and haematological variables were missing at random. Hypothesis tests were two-tailed (p<0·05). We analysed data with Stata (version 13).
Role of the funding source
The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
During the study period, 150 patients were admitted with confi rmed Ebola virus disease. Additionally, six patients who did not have Ebola virus disease were referred and four patients died in transit. Absent laboratory samples were the result of no sample being Table 2 shows baseline characteristics. Median time from admission to discharge amongst survivors was 8 days (IQR 5-12) and median time from admission to death was 4 days (IQR 3-5). Patients who did not have any laboratory investigations were more likely to be younger than 5 years (p=0·003) and female (p=0·033), but otherwise had similar baseline characteristics to those with laboratory results.
The overall case fatality rate for the study period was 37% (55/150). The case fatality rate in those included in this study was 35% (41/118). The case fatality rate was higher in men than in women (40% vs 29%, χ²=1·79; p=0·181) and lower in children than in adults (24% vs 40%, χ²=3·02; p=0·082). Higher disease stage on admission was strongly associated with mortality (66·7%, 32·7%, and 25·8% for stage 3, 2, and 1, respectively; p=0·001). Mean time from symptom onset to admission was shorter in patients who died than in survivors. There was no association between time from symptom onset and disease stage at admission.
The mean cycle threshold in positive patients was 21·4 cycles (SD 4·5), with 41·1% (46/112) of patients having a low cycle threshold. Low cycle threshold on admission was strongly associated with mortality (65·2% vs 13·6%; p<0·001). 15 patients were transferred after positive Ebola virus RT-PCR tests at the referring centre, but tested negative at admission, despite remaining symptomatic. Their survival rate was 100%. Table 3 and the fi gure show biochemistry results for the cohort. Creatinine concentrations were signifi cantly higher in fatal than non-fatal cases (table 3) . Acute kidney injury was common, arising in 50% (52/104) of cases. Acute kidney injury was more common in fatal than non-fatal cases ( but was not associated with outcome. Abnormal liver function was common, with 70% (71/101) of patients having alanine transaminase or aspartate transaminase more than fi ve times the upper limit of normal. Severe hepatitis (aspartate trans aminase >15 times the upper limit of normal) was more common in fatal than non-fatal cases (93% vs 44%; p<0·001). Median aspartate transaminase to alanine transaminase ratio was 2·3, and did not diff er signifi cantly between outcomes. Bilirubin was normal in 87% (79/91) of patients. Raised creatinine kinase concentration was common, and higher in fatal than non-fatal cases (table 3). All patients with a normal creatinine kinase concentration survived. 14 patients had creatinine kinase concentrations higher than 5000 IU/L (upper limit of our assay). Almost all patients with RIFLE-3 acute kidney injury had raised creatinine kinase concentrations (97·1% vs 78·3% with no acute kidney injury; p=0·014). Median C-reactive protein was higher in fatal than non-fatal cases and more fatal cases had C-reactive protein concentrations greater than 100 mg/L (table 3). Lactate was raised in 94% (16/17) of cases.
Higher mean haemoglobin concentration, haematocrit, and median platelet count were associated with mortality. Mean haemoglobin concentration, haematocrit, and platelets in non-survivors versus survivors were 15·5 g/dL versus 13·5 g/dL (n=103; p<0·001) 45·1% versus 39·4% (n=100; p<0·001), and 146 × 10⁹/L versus 197 × 10⁹/L (n=104; p=0·005), respectively (fi gure, table 3). Thrombocytopaenia was more common in non-fatal cases. Severe thrombocytopaenia (<50 × 10⁹/L) was uncommon (3/104 [2·9%]). Low median white cell count, lymphocyte count, and granulocyte count also predicted survival. Median white cell count was 15·8 × 10⁹/L versus 7·9 × 10⁹/L (p<0·001, n=104), median lymphocytes were 4·2 × 10⁹/L versus 2·2 × 10⁹/L (p<0·001, n=104), and granulocytes were 11·5 × 10⁹/L versus 4·3 × 10⁹/L (p=0·001, n=104) in nonsurvivors versus survivors, respectively (fi gure, table 3). Granulo cytosis was present in 42% (44/104) of patients, and lymphocytosis was more common in fatal cases (65% vs 28%; p=0·001). Malaria co-infection was uncommon with 2·5% (3/114) of patients having a positive malaria rapid diagnostic test on admission. In unadjusted analyses, the strongest risk factors for mortality were RIFLE-3 acute kidney injury, severely raised aspartate transaminase, high haematocrit, low Ebola virus RT-PCR cycle threshold, hyperkalaemia, C-reactive protein concentrations higher than 100 mg/dL, and granulo cytosis (table 4) .
Although hyperkalaemia seemed to be associated with RIFLE-3 acute kidney injury, both remained associated with mortality in bivariate analyses (p<0·001). Similarly, haemoglobin concentrations and haematocrit were associated with each other; however, haematocrit remained strongly associated with mortality after adjust ment for haemoglobin concentration (OR 26·9, 95% CI 2·5-289·3). C-reactive protein concentrations remained strongly associated with mortality (16·5, 3·8-71·2), even after adjustment for granulocytosis.
We did multivariate analysis with variables associated with mortality a priori (age, sex, RT-PCR cycle threshold) or in univariate or bivariate analysis. Age was fi tted as a continuous variable. Hyperkalaemia, C-reactive protein concentrations, and granulocytosis seemed to become protective due to co-linearity and were removed to improve stability. We removed haematocrit from the model because it had no eff ect. No interaction terms contributed to the model. Table 4 shows the fi nal model. The strongest independent risk factors for mortality were low Ebola virus RT-PCR cycle threshold and RIFLE-3 acute kidney injury (table 4) . Disease stage on admission was not associated with mortality after adjustment for other risk factors.
Discussion
The natural history of Ebola virus disease is well characterised with a gastrointestinal stage leading to pronounced hypovolaemia, systemic hypoperfusion, and shock in patients who are inadequately fl uid-resuscitated. 4 The extent of multiorgan dysfunction syndrome, which commonly aff ects the renal, hepatic, neurological, and coagulation systems, varies from mild dysfunction to irreversible organ failure and death, but the pathogenesis of Ebola virus disease remains poorly understood. The availability of routine biochemistry and haematological testing is crucial for the improvement of outcomes. Large observational studies are also needed to compare data with animal models and support clinical trials of novel therapeutics.
Most patients (74/118 [63%]) in our cohort were admitted with stage 2 or 3 disease, and had high levels of organ dysfunction and associated metabolic abnormalities. 52 (50%) of 104 patients had acute kidney injury, and raised creatinine concentrations were associated with mortality, supporting earlier published data. 6, 7 Importantly, kidney dysfunction was not restricted to late disease stage, supporting the role of intravenous fl uid treatment in early disease. Acute kidney injury is generally attributed to prerenal causes. 4, 15 However, our data suggest that acute kidney disease might be multifactorial in view of the high prevalence in early disease when dehydration is a less common clinical fi nding. The role of rhabdomyolysis is unclear and should be studied further in view of our almost universal fi ndings of raised creatinine kinase (and its association with acute kidney injury), and disproportionately increased con centrations of aspartate transaminase. However, creatinine kinase was rarely increased to concentrations associated with acute kidney injury, apart from in a few patients who reached the ceiling of our assay measure ment. Subsequent renal injury could also arise due to poor renal perfusion secondary to profound hypovolaemia from gastrointestinal losses, or viral or secondary bacterial sepsis resulting in acute tubular necrosis. 20 Microvascular damage from disseminated intravascular coagulation might also contribute; raised D-dimer was a common fi nding in patients with Sudan Ebola virus 6 and autopsy of infected primates reported fi brinous cellular debris in the glomerulus. 21 Importantly, our results show that Ebola virus disease-associated acute kidney injury can be managed successfully in this setting. Hepatocellular infl ammation has previously been reported in patients with Ebola virus disease. 8, 9 Our results showed that most patients had raised concentrations of alanine transaminase or aspartate transaminase, which was associated with mortality. The fi nding of normal bilirubin concentrations suggests that fulminant hepatic failure is not a major feature consistent with the clinical syndrome recorded. Increased C-reactive protein concentrations and granulocytosis were also associated with mortality, which might refl ect secondary bacterial infection, 21 although all patients were given a thirdgeneration cephalosporin from stage 2 of clinical disease.
Our data are the fi rst reported for haematological abnormalities, and suggest that mortality was associated with increased haemoglobin concentrations and haematocrit. This could be a surrogate marker for intravascular fl uid depletion, widely believed to be associated with poor outcomes. 4 Thrombocytopenia was common and arose in 45% of patients at presentation, but was rarely severe. We were unable to measure coagulation in our cohort, and this should be a priority for future research in view of the frequency and poorly understood nature of haemor rhage in Ebola virus disease. Semi-quantitative Ebola virus viral load measurement is a useful predictor of mortality 8, 12 and was associated with clinical outcome in our study.
Our study had several limitations. The case fatality ratio is lower than others have reported. 7, 10, 11 Although this could be the result of high-standard clinical care, it is possible that there is a survivor bias (ie, patients with Ebola virus disease more likely to survive were admitted to this Ebola treatment centre) because only patients confi rmed to have Ebola were admitted during the study period, and there were time delays before Ebola treatment centre admission. This is supported by the fi nding that some patients were RT-PCR negative at admission, suggesting that they might have already cleared the virus. Caution should be used in comparing case fatality rates between settings. The fi nding that a shorter time from symptom onset to admission was associated with mortality could have been caused by recall bias and survivor bias; symptom onset date was collected from records sent with the patient, which were not always complete. Patients also presented to the Ebola treatment centre at diff erent stages of illness, and had variable amounts of treatment in holding centres before admission.
Because of an isolator failure, 24 consecutive patients had no laboratory testing. The signifi cance of this to our results is unclear. Some assays (aspartate transaminase, alanine transaminase, and creatinine kinase) were limited by their upper limits of detection, potentially underestimating the diff erence between groups. Additionally, baseline creatinine concentrations were estimated based on MDRD scores, which might have overestimated or underestimated the prevalence of acute kidney injury.
Our fi ndings show that the provision of routine laboratory support to an Ebola treatment centre provides an opportunity for improved understanding of disease pathophysiology, and association with clinical disease staging. We noted a previously unreported high prevalence of electrolyte imbalance and organ dys function in all stages of Ebola virus disease. The ability to diagnose and treat these abnormalities at presentation and follow patients' response to treatment will probably improve survival.
The most important aspects of supportive care are aggressive management of intravascular volume depletion, correction of electrolyte abnormalities, and prevention of complications associated with shock. 22 These are underlying tenets of critical care medicine, which can and should be applied in this setting. Improvement of the provision of good supportive care including laboratory analysis is essential to further clarify the pathogenesis and pathophysiology of Ebola virus disease in human beings. In parallel to ongoing intervention studies, this will inform evidence-based protocols to improve outcomes for this outbreak and the next. 
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